Clinical Performance and Safety of STYLAGE® HydroMax

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-09

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

FHAME is a post-market clinical investigation designed to strengthen the clinical evidence supporting the effectiveness of STYLAGE® HydroMax in the treatment of superficial wrinkles, primarily on the cheeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity

NCT04088006

Aging

COMPLETED NA

Effectiveness and Safety of STYLAGE® HYDRO in the Treatment of Face, Neckline Area and Neck

NCT05809739

Aging

COMPLETED NA

Evaluation of the Safety and Performance of an Injectable Hyaluronic Acid Filler

NCT04971876

Lips Enhancement Nasolabial Fold Correction Midface Volume Deficit

COMPLETED NA

Performance and Safety of Semical Dermal Fillers in Facial Rejuvenation

NCT07160777

Facial Aging Skin Rejuvenation Volume Defects in the Mid-face +5 more

ACTIVE_NOT_RECRUITING

Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers

NCT01151436

Facial Wrinkles

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

FHAME is an interventional, post-market, multicentric, prospective, randomized clinical investigation conducted in subjects without any pathology, treated with CE-marked STYLAGE® HydroMax to confirm and update its clinical performance and safety. The primary objective of the study is to assess the mean change from baseline in cheek wrinkle severity, evaluated by an independent blinded assessor at six weeks post-baseline using the Bazin cheek wrinkle scale during live assessments. Clinical performance will be demonstrated if the mean change in the Bazin cheek wrinkle score at six weeks post-baseline is statistically superior in the treatment group (Group A) compared to the control group (Group B). To demonstrate the superiority of STYLAGE® HydroMax compared to no treatment, a total of 81 subjects will be randomized in the study. The overall duration of the study is expected to be approximately seventeen months, including a recruitment period of around six months, a screening period of two weeks, and an investigation period of thirty-six weeks post-randomization for Group A and forty-two weeks for Group B.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging Aesthetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Intervention Arm (Group A): two injection sessions with STYLAGE® HydroMax before Week 6

Subjects will be randomized 2:1 to Group A. During Stage 1, they will receive two STYLAGE® HydroMax injection sessions at baseline and Week 3. In Stage 2, they will be followed for 30 additional weeks (up to Week 36) and will receive a third injection at Week 24 after the first injection.

Group Type EXPERIMENTAL

STYLAGE® HydroMax

Intervention Type DEVICE

3 injection sessions : Group A: at week 0 (V1a), week 3 (V2a), and week 24 (V5a). Group B: at week 6 (V3b), week 3 from V3b (V4b), and week 24 from V3b (V7b)

Control Arm (Group B): No Treatment before Week 6

Subjects will be randomized 2:1 to Group B. In Stage 1, they will receive no treatment until Week 6. Data collected at Week 6 will serve as pre-treatment baseline. In Stage 2, eligible subjects in Group B will receive STYLAGE® HydroMax following the same schedule as Group A. All subjects in Group B will be followed up to 36 weeks after their first STYLAGE® HydroMax injection.

Group Type OTHER

STYLAGE® HydroMax

Intervention Type DEVICE

3 injection sessions : Group A: at week 0 (V1a), week 3 (V2a), and week 24 (V5a). Group B: at week 6 (V3b), week 3 from V3b (V4b), and week 24 from V3b (V7b)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STYLAGE® HydroMax

3 injection sessions : Group A: at week 0 (V1a), week 3 (V2a), and week 24 (V5a). Group B: at week 6 (V3b), week 3 from V3b (V4b), and week 24 from V3b (V7b)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects without any pathology aged between 35 and 70 years old at inclusion.
2. Subjects wishing treatment for the aesthetic improvement of facial wrinkles.
3. Subject having given freely and expressly their informed consent.
4. Subject with a Grade 2 to 5 score on the Bazin cheek wrinkle scale.
5. Subject with the same wrinkle score according to the Bazin cheek wrinkle scale for both cheeks (i.e., symmetrical cheeks).
6. Subject psychologically able to understand investigation related information and to give written informed consent.
7. Subject affiliated to a health social security system.
8. Female of childbearing potential must use a medically accepted contraceptive regimen for at least 12 weeks prior to the start of the investigation and for the duration of the investigation.
9. Subject agreeing not to change any hormonal treatment (including contraceptive treatment and hormone replacement therapy) for the duration of the investigation.
10. Subject agreeing to keep their usual cleansing / care products for the duration of the investigation.
11. Subject agreeing to apply a SPF50 cream when exposed to non-intensive sunlight (i.e., excluding prolonged sun exposure such as sunbathing or extended beach exposure).
12. Subject able to comply with investigation requirements and complete all required visits.
13. Subject agreeing not to receive any other plastic surgery or cosmetic procedure on the face (e.g. dermal fillers, toxin-based treatment, fractional or ablative laser, micro-dermabrasion, chemical peel, noninvasive procedures for skin laxity) for the duration of the investigation.
14. Subject agreeing not to have any planned dental surgery during the investigation.

Exclusion Criteria

1. Pregnant or breastfeeding woman or woman planning a pregnancy during the investigation.
2. Woman less than a year past menopause.
3. Subject with a tattoo, a scar, moles, too many hairs or body hairs (i.e. beard), or anything on the studied zones which might interfere with outcome evaluations.
4. Subject who has been deprived of their freedom by administrative or legal decision or who is under guardianship.
5. Member of the investigating team or family member of a member of the investigating team.
6. Subject in a social or sanitary establishment.
7. Subject having received 6000 euros indemnities for participation in research involving human beings in the 12 previous months, including participation in the present investigation.
8. Subject participating in another research on human beings or who is in an exclusion period of one.
9. Subject who had intensive exposure to sunlight (i.e., prolonged sun exposure such as sunbathing or extended beach exposure) or UV-rays within the previous month and/or for whom intensive exposure to sunlight or UV-rays is foreseen during the clinical investigation.
10. Subject suffering from severe or progressive disease or any other pathology that may interfere with the evaluation of the investigation results.
11. Subject with known history of, or suffering from, autoimmune disease and/or immune deficiency.
12. Subject suffering from inflammatory and/or infectious cutaneous disorders in or near the studied zones (herpes, acne, mycosis, papilloma…). Subject with recurrent herpes in the midface area is eligible if asymptomatic at time of inclusion.
13. Subject having a history of severe allergy or anaphylactic shock including hypersensitivity to HA or to one of the components of the tested device, to antiseptic solution or anesthesia products if applicable.
14. Subject with a history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats.
15. Subject predisposed to keloids or hypertrophic scarring.
16. Subject prone to develop inflammatory skin conditions or has a tendency to bleeding disorders.
17. Subject with a fructose intolerance.
18. Subject who had dental surgery within the 6 weeks prior to the start of the investigation.
19. Subject having received treatment with laser, dermabrasion, surgery, deep chemical peeling, or other ablative procedure on the investigated areas within the 12 months prior to start of the investigation.
20. Subject having received injections of botulinum toxin within the 9 months prior to the start of the investigation.
21. Subject having received an injection with a resorbable filling product in the investigated areas within the 18 months prior to the start of the investigation.
22. Subject having previously received at any time in the past 24 months an injection with a slowly resorbable filling product (polylactic acid, calcium hydroxyapatite, combinations of HA and hypromellose, HA and dextran microbeads or HA and TriCalcium Phosphate…) or with a non-resorbable filling product (polyacrylamide, silicone, combination of methacrylic polymers and collagen, polymer particles …).
23. Subject having previously received at any time in the past 24 months a treatment with tensor threads on the face.
24. Subject having taken medication such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, naproxen…), antiplatelet agents, anticoagulants, vitamin C in the week prior each injection session or who is a chronic user of these medications.
25. Subject undergoing a topical treatment on the test areas or taking either of the following systemic treatments:

1. Antihistamines within the 2 weeks prior to the start of the investigation.
2. Immunosuppressors and/or corticoids within the 4 weeks prior to the start of the investigation.
3. Retinoids within the 6 months prior to the start of the investigation

Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes